Can Peptides Cause Cancer?
The current evidence indicates that peptide therapies, specifically GLP-1 receptor agonists (the most extensively studied peptide class), do not increase cancer risk and can be used safely in patients with type 2 diabetes and obesity, including those with family history of malignancy. However, peptides should be avoided in patients with active malignancy until cancer treatment is complete.
Evidence from GLP-1 Receptor Agonists (Most Robust Peptide Data)
The most comprehensive recent evidence comes from a 2025 systematic review and meta-analysis of 48 randomized controlled trials involving 94,245 participants 1. This high-quality evidence demonstrates:
- No increased risk of thyroid cancer (OR 1.37,95% CI 0.82-2.31) - translating to 1 fewer to 9 more cases per 10,000 patients treated
- No increased risk of pancreatic cancer (OR 0.84,95% CI 0.53-1.35)
- No increased risk of breast cancer (OR 0.95% CI 0.60-1.49)
- No increased risk of kidney cancer (OR 1.12,95% CI 0.78-1.60)
- Likely no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancers
A 2025 multisite cohort study across six countries (98,147 GLP-1RA users vs 2,488,303 DPP-4i users) found no association between GLP-1RA use and thyroid cancer risk (pooled HR 0.81,95% CI 0.59-1.12) 2. Importantly, there was no dose-response relationship with cumulative exposure.
Growth Hormone Peptides and Cancer Considerations
For growth hormone formulations (another major peptide class), clinical practice guidelines explicitly recommend against peptide treatment in patients with active malignancy 3. The evidence regarding cancer survivors is mixed:
- GH therapy can be instituted in childhood cancer survivors after successful remission and an appropriate waiting period
- Long-acting GH formulations like somapacitan have not been prospectively studied in cancer survivors
- The theoretical cancer risk remains hypothetical rather than evidence-based
Endogenous Peptides vs. Therapeutic Peptides: Critical Distinction
It is crucial to distinguish between endogenous peptide levels and therapeutic peptide administration:
- Elevated endogenous insulin-like growth factor peptides (IGF-I, IGF-II) are associated with increased colorectal cancer risk (OR 1.25 for IGF-I, OR 1.52 for IGF-II) 4
- Elevated endogenous C-peptide (insulin production marker) predicts colorectal cancer risk (RR 2.7-3.4 for highest vs. lowest quintile) 5
- However, therapeutic GLP-1 peptides do not replicate these endogenous associations - they appear to have neutral or potentially protective effects
Clinical Algorithm for Peptide Use
Absolute contraindications:
- Active malignancy (any peptide therapy)
- Pregnancy (insufficient safety data)
Proceed with standard monitoring:
- Personal history of cancer (after successful treatment completion and appropriate waiting period)
- Family history of malignancy (no evidence of increased risk)
- Type 2 diabetes or obesity requiring treatment
No additional cancer screening required beyond age-appropriate guidelines for patients on peptide therapies.
Important Caveats
The primary limitation across all studies is short follow-up duration (median 1.8-3.0 years for most trials). While short-term safety is well-established, long-term cancer risk beyond 3-5 years remains incompletely characterized 2, 1. This is particularly relevant given cancer's long latency period.
The 2013 ACCP guidelines note that evidence for dietary supplements containing amino acids and peptides remains insufficient, with some supplements (like vitamin A derivatives) actually increasing lung cancer risk 6. This underscores the importance of distinguishing pharmaceutical-grade peptide therapies from unregulated supplements.
For patients with needle phobia, peptide therapies requiring self-injection are not suitable alternatives 3.